Biogen to present data at AAIC
Biogen will present data from its Alzheimer's disease programs at the Alzheimer's Association International Conference 2017 in London, July 16 to July 20. The planned poster presentations include: Change from Baseline in Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, a Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab. Poster 1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis shows the change in the cognitive and functional subscores, which are derived from the previously reported clinical dementia rating score for the overall and early Alzheimer's disease populations in the 1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b. This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com. Signs and Symptoms of Alzheimer's Disease Noted in Health Records up to 5 Years Prior to Diagnosis. Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer's disease diagnosis.